CART-ddBCMA demonstrated a 100% overall response rate in patients with relapsed/refractory multiple myeloma. Patients with both multiple myeloma (MM) and secondary immunodeficiencies (SID) face... The results of the trial were presented during the 2022 ESMO Congress by Chunkang Chang, MD, PhD.